V5med

Hsinchu City, Taiwan (R.O.C.) All Taiwan companies → — Founded 2023 (Note: Some sources indicate V5 Technologies, the parent company, was established in 2014, and V5med was established in 2024 with a primary focus on Medical Image AI.)

Imaging AI Specialist

Oncology Pulmonology Radiology

Oncology AI Radiology & Imaging AI

unknown (Note: One source indicates "No funding" for V5med, while another indicates "尚未IPO" (not yet IPO) and a capital of 35 million NTD.)

Claim this company

Products

V5med Lung AI

V5med Inc.

Oncology AI

V5med Lung AI is an FDA-cleared AI-powered software that assists radiologists in detecting pulmonary nodules (4-30 mm) in chest CT images, enhancing accuracy and reducing interpretation time.

Contact for pricing

See all 1 product →

About V5med

V5med is a healthcare AI company that develops AI-powered diagnostic tools to address clinical needs, with an initial focus on lung cancer and cardiopulmonary diseases. The company’s mission is to provide earlier, more accurate, and more accessible diagnostics to patients globally. Their FDA-cleared platform assists in the interpretation of low-dose CT (LDCT) scans for the detection and tracking of lung nodules, and is currently in use in clinical settings. Beyond the U.S., V5med’s expanded AI suite also offers analysis for emphysema, pulmonary fibrosis, and coronary artery calcification (CAC), with these modules deployed across Asia and under development for future regulatory clearance in other markets.

Founded with strong engineering expertise from the semiconductor industry, V5med integrates AI algorithms, clinical insights, and scalable system design to deliver practical and trustworthy tools for physicians. Their solutions are clinically validated to enhance nodule detection sensitivity by over 95% and can improve radiologist accuracy by up to 20%. The system is compatible with Lung-RADS® and optimized for detecting ground-glass nodules (GGNs), making it suitable for lung cancer screening programs and routine chest CT workflows. V5med’s AI solutions are PACS-integrated, vendor-neutral, and scalable across radiology networks and screening centers, working closely with clinical partners to ensure usability and real-world impact.

Focus Areas

AI-powered diagnostic tools lung cancer screening lung nodule detection and tracking cardiopulmonary diseases emphysema pulmonary fibrosis coronary artery calcification (CAC) smart medical devices surgical assistance systems.

Business Intelligence

Technology

Cloud-native, Deep Convolutional Neural Network (CNN)-based algorithms, PACS-integrated, vendor-neutral, DICOM 3.0 standard compatible

What Physicians Need to Know

AI-Powered Lung Nodule Detection & Tracking

V5med's core offering is an FDA-cleared AI-powered computer-aided detection (CADe) system, V5med Lung AI, designed to assist radiologists in rapidly and accurately detecting and evaluating pulmonary nodules in low-dose CT (LDCT) lung cancer screening workflows. It automatically annotates nodules, provides real-time measurements (diameter, volume, type like GGN), and offers Lung-RADS® classification. The system also supports longitudinal image comparison, precisely aligning nodules across different timepoints and quantifying growth trends such as volume doubling time (VDT).

Comprehensive Cardiopulmonary Disease Analysis

Beyond lung nodules, V5med's expanded AI suite (currently deployed in Asia and under development for other markets) provides analysis for emphysema, pulmonary fibrosis, and coronary artery calcification (CAC) from a single CT scan.

Key Differentiators

V5med stands out with its high sensitivity and accuracy (overall sensitivity: 95.6%; 4–5mm nodule detection: 92.8%; GGO nodule detection: 95.7%), ability to enhance radiologist nodule detection accuracy by over 20%, and reduction in review time. It's also the first Taiwanese company to receive U.S. FDA 510(k) clearance for low-dose CT-based lung cancer screening AI. The system is hardware-agnostic, validated across multiple CT scanner brands, and supports DICOM GSPS format for seamless PACS and DICOM viewer integration.

Technology Stack

V5med leverages advanced AI algorithms, specifically a Deep Convolutional Neural Network (CNN)-based algorithm, built on over a decade of expertise in high-speed imaging, deep learning, and computer vision. The system integrates algorithm logic and a database on the same server, accepting chest CT images from PACS, RIS, or directly from a CT scanner.

Smart Medical Devices & Surgical Assistance

V5med is actively expanding from diagnostic AI into smart medical devices and surgical assistance systems, with a clear focus on improving patient outcomes through intelligent, clinician-centered technology.

Physician Tip

V5med's Lung AI system acts as a clinical-grade diagnostic assistant, enhancing nodule detection accuracy and consistency in lung cancer screening. It provides automated nodule tracking and change analysis, offering quantitative growth trends and risk assessment based on Lung-RADS® and Fleischner Guidelines. This streamlines reporting and supports standardized diagnostic decisions. The system is designed for concurrent read mode, displaying AI analysis results alongside original CT images, and is not intended to be used as the sole basis for diagnosis.

V5med's AI solutions are PACS-integrated, vendor-neutral, and scalable across radiology networks and screening centers. They support DICOM GSPS format for seamless PACS and DICOM viewer integration. The system accepts chest CT images from a PACS system, Radiological Information System (RIS), or directly from a CT scanner. V5med also works closely with clinical partners to ensure usability and interoperability.

At a glance

Founded 2023 (Note: Some sources indicate V5 Technologies, the parent company, was established in 2014, and V5med was established in 2024 with a primary focus on Medical Image AI.)

HQ Hsinchu City, Taiwan (R.O.C.) · Taiwan

CEO Michael Huang

Funding unknown (Note: One source indicates "No funding" for V5med, while another indicates "尚未IPO" (not yet IPO) and a capital of 35 million NTD.)

Products 1

Products by V5med

1 product in the directory

V5med Lung AI

V5med Inc.

Oncology AI

V5med Lung AI is an FDA-cleared AI-powered software that assists radiologists in detecting pulmonary nodules (4-30 mm) in chest CT images, enhancing accuracy and reducing interpretation time.

Contact for pricing

What the Web Says

V5med is a company that has developed an AI-powered software called V5med Lung AI, designed to assist radiologists in detecting pulmonary nodules in chest CT images. The software aims to improve detection rates, reduce missed diagnoses, and accelerate interpretation and reporting. While there isn't extensive information available on employer reviews specifically for "V5med," there are some general reviews for "V5 Group" and "V5 Global" which may or may not be related. The product itself appears to be well-regarded in its clinical application.

Overall: Positive

Strengths

Increases radiologist nodule detection rate by over 20%
Reduces missed diagnoses and review time
Accelerates physicians' interpretation and reporting procedures
Precisely detects small (4mm-6mm) and GGO type nodules with high sensitivity
Provides ACR Lung-RADS and Fleischner Society Guideline support
Cross-platform compatibility and hardware agnostic

Limitations

Does not replace radiologist's critical judgment or diagnostic processes
Should not be used in isolation from the original CT series
Limited public employer reviews specifically for "V5med"

Based on reviews from: V5med Lung AI, How V5 Technologies Transitioned from Semiconductor Smart..., Working at V5: Employee Reviews | Indeed.com, K242919 - Ining Cheng - accessdata.fda.gov, TPLC - Total Product Life Cycle - accessdata.fda.gov, Indeed.com, Reddit

Last updated: 2026-10-20

Videos

News, demos, and interviews about V5med.

Loading videos...

Videos load interactively. If none appear, search YouTube for V5med →

View all on YouTube

Press & Coverage

V5med Inc. Introduction

V5med Becomes First Taiwanese Company to Receive U.S. FDA 510(k) Clearance for Lung Cancer Screening AI

V5med's Lung AI system received U.S. FDA 510(k) clearance in March 2025, making it the first Taiwanese company to achieve this approval for low-dose CT-based lung cancer screening. This clearance paves the way for V5med's strategic expansion into North America, Latin America, the Middle East, and other global markets.

2025-06

Institute for Biotechnology and Medicine Industry (IBMI)

From Semiconductors to Lung Cancer: V5med's Thailand Expansion

V5med, a spin-off from V5 Technologies, has successfully adapted AI imaging technology from semiconductor inspection for healthcare, specifically for lung nodule detection. Their lung nodule detection system achieved both Taiwan's TFDA and U.S. FDA approvals by March 2025, and the company is now expanding into ASEAN countries, with a focus on Thailand.

2026-02

Clairvo Technologies

V5med and Clairvo Technologies to Enter into an Business Alliance Agreement

V5med Inc. and Clairvo Technologies Co., Ltd. entered into an exclusive business alliance agreement on April 17, 2024, to market V5med's medical device program in Japan. This program is a chest CT imaging diagnostic support software that assists in detecting lung nodules and has already obtained TFDA Class II certificates in Taiwan.

2024-04

V5med Inc. Introduction

Congratulations to V5 Technologies on its successful IPO on March 30

V5 Technologies, the parent company of V5med, successfully completed its IPO on March 30, 2026. This milestone is expected to fuel V5med's continued advancements in AI-powered medical imaging, global expansion, and delivery of healthcare innovation.

2026-05

V5med Inc. Introduction

V5med Expands into the Thailand Market

V5med's expansion into the Thailand market was highlighted by the Institute for Biotechnology and Medicine Industry (IBMI), showcasing their transition from semiconductor AI technology to medical imaging innovation. Their products are currently being adopted and tested by major private and public hospitals in Thailand.

2026-05

Biomedicines

Artificial Intelligence Assisted Computational Tomographic Detection of Lung Nodules for Prognostic Cancer Examination: A Large-Scale Clinical Trial

This peer-reviewed article details a large-scale clinical trial on AI-assisted CT detection of lung nodules for prognostic cancer examination. V5 Technologies collaboratively partnered with prestigious institutions such as Taipei Veterans General Hospital, National Taiwan University Hospital, and the Taiwan Lung Cancer Society to develop V5 Lung AI.

2023-01

FDA

V5med Lung AI 510(k) Premarket Notification

The FDA's 510(k) Premarket Notification for V5med Lung AI (K242919) indicates its regulatory clearance as a Computer-Aided Detection (CAD) software. This software assists radiologists in detecting pulmonary nodules (4-30 mm diameter) in CT scans for asymptomatic populations, providing adjunctive information to highlight regions of interest.

2026-01

V5med Inc. Introduction

HIMSS 2026: Bringing AI-Powered Lung Cancer Detection to the Global Stage

V5med showcased its AI-Powered Lung CT Nodule Detection Software at HIMSS 2026 in Las Vegas as part of the Taiwan MedTech Pavilion. This participation allowed V5med to present its innovations to healthcare leaders, physicians, and technology partners globally.

2026-05

Frequently Asked Questions

What specific AI-powered diagnostic tools does V5med offer for lung cancer screening and the detection/tracking of lung nodules?

V5med specializes in AI-powered solutions designed to enhance the accuracy and efficiency of lung cancer screening. Their tools leverage advanced algorithms to detect and track lung nodules over time, aiding physicians in early diagnosis and personalized treatment planning. These systems are built to integrate with existing imaging workflows, providing quantitative analysis and risk stratification for suspicious findings.

How do V5med's AI solutions assist in the diagnosis and management of other cardiopulmonary diseases like emphysema and pulmonary fibrosis, beyond lung cancer?

Beyond lung cancer, V5med's AI platforms extend their capabilities to other significant cardiopulmonary diseases such as emphysema and pulmonary fibrosis. The AI analyzes imaging data to identify subtle patterns and changes indicative of these conditions, assisting in early diagnosis, disease progression monitoring, and treatment response assessment. This comprehensive approach aims to provide a more holistic view of a patient's cardiopulmonary health.

Does V5med's technology include the assessment of coronary artery calcification (CAC) and how does it integrate with their lung screening tools?

V5med's technology incorporates the assessment of coronary artery calcification (CAC) as part of its comprehensive cardiopulmonary analysis. By analyzing the same CT scans used for lung screening, the AI can simultaneously quantify CAC, providing valuable insights into a patient's cardiovascular risk. This integrated approach allows for a more efficient and thorough assessment of both pulmonary and cardiac health from a single imaging study.

What is V5med's approach to regulatory compliance and data security for its AI-powered diagnostic tools and smart medical devices?

V5med prioritizes regulatory compliance and robust data security for all its AI-powered diagnostic tools and smart medical devices. Their products are developed in accordance with relevant medical device regulations (e.g., FDA, CE Mark) and adhere to stringent data privacy standards like HIPAA and GDPR. They employ advanced encryption and security protocols to protect patient data and ensure the integrity of their diagnostic insights.

What kind of support and training does V5med provide for physicians and healthcare administrators implementing their AI solutions and surgical assistance systems?

V5med offers comprehensive support and training programs to ensure seamless integration and effective utilization of their AI solutions and surgical assistance systems. This includes on-site training, online tutorials, dedicated technical support, and clinical application specialists. Their goal is to empower healthcare professionals to maximize the benefits of their technology, ensuring optimal patient care and operational efficiency.

Can V5med's AI solutions be integrated with existing electronic health record (EHR) systems and picture archiving and communication systems (PACS)?

V5med's AI solutions are designed for seamless integration with existing electronic health record (EHR) systems and picture archiving and communication systems (PACS). They utilize industry-standard protocols and APIs to ensure interoperability, allowing for efficient data exchange and workflow integration. This enables healthcare providers to access AI-generated insights directly within their familiar clinical environments.

What is the pricing model for V5med's AI-powered diagnostic tools and smart medical devices, and are there options for different practice sizes?

V5med offers flexible pricing models for its AI-powered diagnostic tools and smart medical devices, designed to accommodate various practice sizes and healthcare systems. Options may include subscription-based licensing, per-study fees, or enterprise-wide agreements. They work closely with clients to develop a pricing structure that aligns with their budget and operational needs, ensuring accessibility to their advanced technologies.

Related Companies

Suggest an Edit → | Report an issue